Madrigal Pharmaceuticals Q2 Earnings Top Estimates on $364.3M Revenue
Madrigal Pharmaceuticals reports a narrower-than-expected Q2 loss and revenue growth of 71.2% year-over-year. Madrigal Pharmaceuticals posted a Q2 GAAP loss per share of $1.99, beating estimates by $0.65. Revenue reached $364.3 million, up 71.2% from the same period last y